Thursday 12 May 2016

Leading South African Health Insurer Approves Reimbursement of SIR-Spheres® Y-90 resin microspheres
Discovery Health, the leading South African private health insurer, has agreed to reimburse SIR-Spheres Y-90 resin microspheres for the treatment of all forms of inoperable liver tumours.


Thursday 31 March 2016

SIR-Spheres® Y-90 resin microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says

Sirtex (ASX:SRX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer (hepatocellular carcinoma or HCC).

Read PDF Read PDF

Other languages:
Wednesday 16 March 2016

Netherlands Healthcare Institute Approves Reimbursement of Selective Internal Radiation Therapy (SIRT)

The Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed on or are intolerant to prior chemotherapy.

Read PDF Read PDF



For more news, select news categories from the menu.


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×